by Scott Larrivee | Oct 16, 2025 | News
The following is a copy of a press release issued by Clarity Pharmaceuticals Sydney, Australia 16 October 2025 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products...
by Scott Larrivee | Oct 14, 2025 | News
Agreement includes Actinium-225 (Ac-225) and Lutetium-177 (Lu-177) to support Ariceum’s therapeutic programs WEST VALLEY CITY, Utah and BERLIN, Germany – Oct. 14, 2025 – Nusano, a physics company transforming the production of radioisotopes, and Ariceum Therapeutics...
by Scott Larrivee | Jun 26, 2025 | News
The following is a copy of a press release issued by Cellectar Biosciences Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for...
by Scott Larrivee | Apr 17, 2025 | News
The following is a copy of a press release issued by Clarity Pharmaceuticals on April 17, 2025 in Australia. Minor edits have been made in this copy to account for English spelling preferences in the United States. Highlights Clarity has signed a commercial-scale...
by Scott Larrivee | Dec 9, 2024 | News
VALENCIA, Calif. and SYDNEY, Australia – Dec. 9, 2024 – Nusano, a physics company transforming the production of radioisotopes, and GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid...
